Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.66 |
| ▸ | NPY4R | P50391 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.66 |
| ▸ | GLP1R | P43220 | 11/20 | 0.65 |
| ▸ | GCGR | P47871 | 7/20 | 0.65 |
| ▸ | GIPR | P48546 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cecropin Ad SCHEMBL29842479 | 0.92 | NPY1R (0.68) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL31182544 | 0.91 | NPY1R (0.69) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| Cecropin A SCHEMBL29361111 | 0.91 | KEAP1 (0.67) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL31182815 | 0.91 | NPY2R (0.73) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31092058 | 0.90 | CXCR4 (0.67) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29352195 | 0.90 | NPY2R (0.70) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31664370 | 0.90 | RXFP1 (0.68) | GLP1RKEAP1 | |
| SCHEMBL31182745 | 0.90 | NPY1R (0.71) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182986 | 0.90 | PTH1R (0.68) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182564 | 0.90 | NPY1R (0.70) | CXCR4NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025018943-A1 | BIODEGRADABLE POLYION COMPLEX NANOPARTICLES OF CATIONIC ANTIMICROBIALS FOR ACTIVATABLE ANTIBACTERIAL THERAPY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-01-23 | — | — | WO | claimed |
| WO-2024184403-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR BIOME APS (DK) | 2024-09-12 | — | — | WO | claimed |
| CN-118207231-A | Preparation method and application of antibacterial peptide Cecropin P1 | 西北农林科技大学 | 2024-06-18 | — | — | CN | claimed |
| EP-3390663-B1 | METHOD FOR THE DETECTION OF A SEXUALLY TRANSMITTED INFECTIOUS PATHOGEN | SELFDIAGNOSTICS OUE (EE) | 2024-04-17 | — | — | EP | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20230160021-A1 | METHOD FOR THE DETECTION OF A SEXUALLY TRANSMITTED INFECTIOUS PATHOGEN | SELFDIAGNOSTICS DEUTSCHLAND GMBH (DE) | 2023-05-25 | — | — | US | claimed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| CN-110531075-B | Pathogenic bacteria immunoassay biosensor based on antibacterial peptide-phosphate nano compound and preparation method and application thereof | 军事科学院军事医学研究院军事兽医研究所 | 2022-06-14 | — | — | CN | claimed |
| CN-114106937-A | Contact lens care solution | 东南大学 | 2022-03-01 | — | — | CN | claimed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| EP-3574909-B1 | POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | disclosed |
| CN-112647282-B | Antibacterial finishing method of silk fabric | 湖南寐家居科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220073565-A1 | DE NOVO DESIGN OF PROTEIN SWITCHES FOR TUNABLE CONTROL OF PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-10 | — | — | US | disclosed |
| US-20220064623-A1 | ENDOLYSIN VARIANT | SASINAPAS CO., LTD. (TH) | 2022-03-03 | — | — | US | disclosed |
| CN-114106937-A | Contact lens care solution | 东南大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20220030855-A1 | FUNCTIONALIZED SET OF CARBON ATOMS IN THE SP2 HYBRIDIZATION STATE, A METHOD FOR PREPARING IT AND ITS USES, IN PARTICULAR FOR RENDERING A SURFACE ANTIBACTERIAL | COMMISSARIAT A I'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | CXCR4 2789/4885NPY1R 4203/4885NPY2R 4170/4885 |
| US-20220030855-A1 | FUNCTIONALIZED SET OF CARBON ATOMS IN THE SP2 HYBRIDIZATION STATE, A METHOD FOR PREPARING IT AND ITS USES, IN PARTICULAR FOR RENDERING A SURFACE ANTIBACTERIAL | SIGLEC7, SET, SIGLEC9 | CXCR4 90/4885NPY1R 2647/4885NPY2R 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.